At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 259 enrolled
Drug / intervention
AC-201, 25mg +3 moredrug
Likely dose
AC-201, 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase II Study of AC-201 in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating AC-201, 25mg, AC-201, 50mg, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 259 participants across 21 sites in 2 countries.
Detailed Summary
This is a 24-week randomized placebo-controlled study to investigate the effect of an oral IL-1beta inhibitor AC-201 in patients with type 2 diabetes mellitus already treated on different background diabetes therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesTaiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionFeb 2012
Study CompletionMar 2012
TodayJul 2026
First PostedJan 13, 2011
Enrollment StartJan 1, 2011
Primary CompletionFeb 1, 2012
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.5 years ago
Interventions
AC-201, 25mgdrug
Capsule, 25mg BID
AC-201, 50mgdrug
Capsule, 50mg BID
AC-201, 75mgdrug
Capsule, 75mg BID
Placebodrug
Placebo BID